期刊文献+

从六经辨治新冠肺炎及其变证 被引量:4

Treatment for COVID-2019 and Its Variation Based on Liujingbianzhi Theory
原文传递
导出
摘要 本文通过对新型冠状病毒肺炎(以下简称"新冠肺炎")临床发病特点及证候规律的总结,认为运用中医药治疗新冠肺炎有其独特的优势,尤其是运用《伤寒论》六经辨证,选用经方治疗新冠肺炎有其独特的疗效,在临床中形成了初步方案。认为新冠肺炎病发之初病在太阳,可继传少阳、阳明,若失治误治或素体正虚,可迅速内陷三阴,变生他证;临证中可单经发病,也可多经合病。不管病在何经,务需遵循"祛邪气,保胃气,存津液",莫忘"培土生金"。若能从六经精准辨证,遣方用药,在临证中往往能收到现代医学无法比拟的独特疗效。 To summarize the clinical characteristics and syndrome patterns of COVID-2019, and suggest application of traditional Chinese medicine to the treatment for COVID-2019 due to its unique advantages. Based on Liujingbianzhi theory in Shanghanlun, classical compounds were selected to treat COVID-2019, which showed unique curative effect and formed a preliminary treatment plan in clinic. It suggested that the initial onset of COVID-2019 began from Taiyang Meridian, then to Shaoyang and Yangming. If it was mistreated or the body was weak, it might quickly affect Sanyin and change its syndrome(Bianzheng). The disease may affect single Meridian or multiple meridians. The basic principle of treatment is "Quxieqi, Baoweiqi, Cunjinye " and "Peitushengjin". Compared with the modern medicine, traditional Chinese medicine compounds based on "Liujingbianzheng" theory may receive unique effects.
作者 胡久略 闫东升 商健 Hu Jiulue;Yan Dongsheng;Shang Jian(Zhang Zhongjing College of Chinese Medicine,Nanyang institute of Technology,Nanyang 473004;Henan Key Laboratory of Zhang Zhongjing Formulae and Herbs for Immunoregulation,Nanyang 473004;The Third Affiliated Hospital of Henan University of Traditional Chinese Medicine,Zhengzhou 450046)
出处 《中药药理与临床》 CAS CSCD 北大核心 2020年第2期90-92,共3页 Pharmacology and Clinics of Chinese Materia Medica
基金 国家自然科学基金项目(编号:U1504826)。
关键词 新型冠状病毒肺炎 六经 辨证论治 变证 方药 COVID-2019 Liujing Bianzhenglunzhi Bianzheng compounds
  • 相关文献

参考文献4

二级参考文献17

共引文献292

同被引文献47

引证文献4

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部